Chapter 27: Advances Imminent in Antiangiogenesis Therapeutics

Advances imminent in antiangiogenesis therapeutics Angiogenesis inhibitors have interested cancer researchers since 1971, when scientist and angiogenesis pioneer Judah Folkman first presented his finding in the New England Journal of Medicine that tumor growth depends on angiogenesis. Despite many efforts to develop angiogenesis inhibitors, this class of drugs has experienced a long and difficult road to market. After more than 30 years of research, angiogenesis inhibitors finally experienced a series of breakthroughs in 2004 and 2005, which began with the approval of Genentech's bevacizumab (Avastin). The Food and Drug Administration's (FDA's) approval of bevacizumab for colon and rectum cancer in 2004 marked the entry of a new class of powerful drugs into the cancer market. Shortly thereafter, the FDA approved Eyetech Pharmaceuticals' pegap-tanib (Macugen), demonstrating that angiogenesis inhibitors also impact ocular disease. Since the approval of these drugs, which essentially proved the concept of angiogenesis, interest in developing angiogenesis inhibitors ...

Users without subscription are not able to see the full content on this title. Please, subscribe or login to access all content on this website.

• Buy The Book